Vivo Capital LLC Increases Position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Vivo Capital LLC raised its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 57.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,913,623 shares of the biotechnology company’s stock after buying an additional 700,333 shares during the period. Aurinia Pharmaceuticals comprises approximately 1.2% of Vivo Capital LLC’s investment portfolio, making the stock its 23rd biggest position. Vivo Capital LLC owned 2.08% of Aurinia Pharmaceuticals worth $12,592,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Aurinia Pharmaceuticals by 3.1% during the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock valued at $6,063,000 after buying an additional 28,129 shares during the period. Toronto Dominion Bank boosted its position in shares of Aurinia Pharmaceuticals by 26.3% during the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 2,575 shares during the period. Wells Fargo & Company MN boosted its position in shares of Aurinia Pharmaceuticals by 35.5% during the second quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 20,432 shares during the period. Swiss National Bank boosted its position in shares of Aurinia Pharmaceuticals by 14.0% during the second quarter. Swiss National Bank now owns 111,800 shares of the biotechnology company’s stock valued at $738,000 after buying an additional 13,700 shares during the period. Finally, Redmile Group LLC purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $2,101,000. Institutional investors and hedge funds own 31.96% of the company’s stock.
AUPH has been the subject of several recent analyst reports. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Aurinia Pharmaceuticals in a research report on Tuesday, June 4th. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 5th. Royal Bank of Canada reiterated a “buy” rating and issued a $11.00 price target on shares of Aurinia Pharmaceuticals in a report on Thursday, August 8th. Finally, Citigroup initiated coverage on Aurinia Pharmaceuticals in a report on Monday. They issued an “outperform” rating and a $14.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Aurinia Pharmaceuticals has an average rating of “Buy” and an average price target of $15.18.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 13,231.97% and a negative return on equity of 50.08%. On average, research analysts forecast that Aurinia Pharmaceuticals Inc will post -0.68 earnings per share for the current fiscal year.
Aurinia Pharmaceuticals Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: Why do analysts give a neutral rating?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.